Sitagil
Generic Name
Sitagliptin
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| sitagil 25 mg tablet | ৳ 8.00 | ৳ 80.00 |
Description
Overview of the medicine
Sitagil 25 mg Tablet contains Sitagliptin, an oral antidiabetic medication used to improve glycemic control in adults with type 2 diabetes mellitus. It works by inhibiting the dipeptidyl peptidase-4 (DPP-4) enzyme.
Uses & Indications
Dosage
Adults
The usual recommended dose is 100 mg once daily. However, 25 mg dose is typically used for patients with severe renal impairment or end-stage renal disease.
Elderly
No dose adjustment required based on age, but renal function should be assessed before prescribing.
Renal_impairment
For mild renal impairment (CrCl ≥ 50 mL/min), no dose adjustment. For moderate (CrCl ≥ 30 to < 50 mL/min), 50 mg once daily. For severe (CrCl < 30 mL/min) or end-stage renal disease requiring dialysis, 25 mg once daily.
How to Take
Administer orally once daily, with or without food.
Mechanism of Action
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It increases the levels of active incretin hormones (GLP-1 and GIP), which enhance glucose-dependent insulin secretion from the pancreas and decrease glucagon secretion, leading to improved glycemic control.
Pharmacokinetics
Onset
Within hours of administration, contributing to glucose lowering effects.
Excretion
Primarily excreted unchanged in urine (about 79% within 4 days). Renal excretion is the major elimination route.
Half life
Approximately 12.4 hours.
Absorption
Rapidly absorbed after oral administration, with peak plasma concentrations reached in 1 to 4 hours. Absolute bioavailability is approximately 87%.
Metabolism
Minimally metabolized; primary metabolism via CYP3A4, with minor contribution from CYP2C8. Main metabolite is inactive.
Side Effects
Contraindications
- Hypersensitivity to Sitagliptin or any component of the formulation.
- Patients with type 1 diabetes mellitus.
- Diabetic ketoacidosis.
Drug Interactions
Digoxin
Slight increase in digoxin plasma levels, monitor carefully.
Cyclosporine
No clinically meaningful interaction.
Metformin, Sulfonylureas, Thiazolidinediones, Insulin
No clinically significant pharmacokinetic interactions when co-administered; however, dose adjustments of concomitant medications may be necessary to minimize hypoglycemia risk.
Storage
Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, seek medical attention immediately. Sitagliptin is modestly dialyzable. Clinical monitoring and supportive care are recommended.
Pregnancy & Lactation
Pregnancy Category B. Use only if clearly needed. Unknown if excreted in human milk, exercise caution if used during breastfeeding.
Side Effects
Contraindications
- Hypersensitivity to Sitagliptin or any component of the formulation.
- Patients with type 1 diabetes mellitus.
- Diabetic ketoacidosis.
Drug Interactions
Digoxin
Slight increase in digoxin plasma levels, monitor carefully.
Cyclosporine
No clinically meaningful interaction.
Metformin, Sulfonylureas, Thiazolidinediones, Insulin
No clinically significant pharmacokinetic interactions when co-administered; however, dose adjustments of concomitant medications may be necessary to minimize hypoglycemia risk.
Storage
Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
In case of overdose, seek medical attention immediately. Sitagliptin is modestly dialyzable. Clinical monitoring and supportive care are recommended.
Pregnancy & Lactation
Pregnancy Category B. Use only if clearly needed. Unknown if excreted in human milk, exercise caution if used during breastfeeding.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 2-3 years from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
Approved by regulatory authorities (e.g., FDA, DGDA)
Patent Status
Off-patent (in many countries, allowing generics)
Clinical Trials
Extensive clinical trials have demonstrated Sitagliptin's efficacy and safety in improving glycemic control in type 2 diabetes, both as monotherapy and in combination with other antidiabetic agents.
Lab Monitoring
- Fasting plasma glucose (FPG)
- HbA1c levels
- Renal function (eGFR/CrCl) periodically
Doctor Notes
- Educate patients on symptoms of pancreatitis (severe abdominal pain).
- Monitor for signs of hypersensitivity reactions.
- Assess renal function before initiating treatment and periodically thereafter.
Patient Guidelines
- Take Sitagil exactly as prescribed by your doctor.
- Do not stop taking the medicine without consulting your doctor.
- Maintain a healthy diet and exercise regimen.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose and continue with your regular schedule. Do not double the dose.
Driving Precautions
Sitagliptin alone is unlikely to affect driving ability. However, if used in combination with a sulfonylurea or insulin, hypoglycemia may occur, which can impair concentration and reaction time. Patients should be advised about the risk of hypoglycemia and how to manage it before driving.
Lifestyle Advice
- Follow a balanced diet for diabetes management.
- Engage in regular physical activity.
- Monitor blood sugar levels regularly as advised by your doctor.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Sitagil Brand
Other medicines available under the same brand name
